article · Discover Immunity.
The gut microbiome’s capacity to produce immunomodulatory metabolites is increasingly recognized as a potent determinant of cancer immunotherapy outcomes. This review uniquely integrates emerging data on engineered microbial metabolite production—through synthetic biology, dietary modulation, rational probiotics, and postbiotic therapies—and maps their clinical translation as immunotherapeutic agents. We critically analyze short-chain fatty acids, tryptophan metabolites, bile acids, and polyamines, highlighting their context-specific immune effects and biomarker potential. Moreover, we outline innovative engineering strategies, precision microbiome tools, and personalized therapeutic platforms that reposition microbial metabolites as programmable bioactive drugs. This synthesis aims to guide the next phase of clinical application and regulatory development in microbiome-informed oncology.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.1007/s44368-026-00019-w
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
